drugset / Trial / NCT02827266

A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis

NCT02827266

Phase 3 Completed 122 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the effect of epoetin beta (NeoRecormon) on correction of anemia and quality of life in participants with diabetes and chronic renal failure and who are not receiving dialysis.

Timeline

Start
2005-10
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 60 iu/kg Subcutaneous

Indications